248 related articles for article (PubMed ID: 11014174)
21. HIV CTL escape: at what cost?
Smith SM
Retrovirology; 2004 May; 1():8. PubMed ID: 15169568
[TBL] [Abstract][Full Text] [Related]
22. Determination of a major histocompatibility complex class I restricting simian immunodeficiency virus Gag241-249 epitope.
Tsukamoto T; Dohki S; Ueno T; Kawada M; Takeda A; Yasunami M; Naruse T; Kimura A; Takiguchi M; Matano T
AIDS; 2008 May; 22(8):993-4. PubMed ID: 18453861
[No Abstract] [Full Text] [Related]
23. Rates of HIV immune escape and reversion: implications for vaccination.
Davenport MP; Loh L; Petravic J; Kent SJ
Trends Microbiol; 2008 Dec; 16(12):561-6. PubMed ID: 18964018
[TBL] [Abstract][Full Text] [Related]
24. Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis.
Mascarell L; Fayolle C; Bauche C; Ladant D; Leclerc C
J Virol; 2005 Aug; 79(15):9872-84. PubMed ID: 16014948
[TBL] [Abstract][Full Text] [Related]
25. Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model.
Earl PL; Wyatt LS; Montefiori DC; Bilska M; Woodward R; Markham PD; Malley JD; Vogel TU; Allen TM; Watkins DI; Miller N; Moss B
Virology; 2002 Mar; 294(2):270-81. PubMed ID: 12009868
[TBL] [Abstract][Full Text] [Related]
26. Avoiding deceptive imprinting of the immune response to HIV-1 infection in vaccine development.
Muller S
Int Rev Immunol; 2004; 23(5-6):423-36. PubMed ID: 15370274
[TBL] [Abstract][Full Text] [Related]
27. Vaccines. Monkey puzzles.
Cohen J
Science; 2002 Jun; 296(5577):2325-6. PubMed ID: 12089425
[No Abstract] [Full Text] [Related]
28. In vivo fitness costs of different Gag CD8 T-cell escape mutant simian-human immunodeficiency viruses for macaques.
Loh L; Batten CJ; Petravic J; Davenport MP; Kent SJ
J Virol; 2007 May; 81(10):5418-22. PubMed ID: 17344299
[TBL] [Abstract][Full Text] [Related]
29. DNA prime and protein boost immunization with innovative polymeric cationic core-shell nanoparticles elicits broad immune responses and strongly enhance cellular responses of HIV-1 tat DNA vaccination.
Castaldello A; Brocca-Cofano E; Voltan R; Triulzi C; Altavilla G; Laus M; Sparnacci K; Ballestri M; Tondelli L; Fortini C; Gavioli R; Ensoli B; Caputo A
Vaccine; 2006 Jul; 24(29-30):5655-69. PubMed ID: 16781023
[TBL] [Abstract][Full Text] [Related]
30. Cytotoxic T lymphocytes in AIDS pathogenesis: lessons to be learned from the macaque model of simian immunodeficiency virus infection.
Geretti AM; Hulskotte E; Osterhaus AD
J Gen Virol; 1998 Mar; 79 ( Pt 3)():415-21. PubMed ID: 9519818
[No Abstract] [Full Text] [Related]
31. Tat toxoid: its potential role as an HIV vaccine.
Lambert J
J Hum Virol; 1998; 1(4):249-50. PubMed ID: 10195248
[No Abstract] [Full Text] [Related]
32. [HIV vaccine].
Matano T
Nihon Rinsho; 2005 May; 63 Suppl 5():659-65. PubMed ID: 15954426
[No Abstract] [Full Text] [Related]
33. HIV-1 Tat vaccines.
Ensoli B; Cafaro A
Virus Res; 2002 Jan; 82(1-2):91-101. PubMed ID: 11885958
[No Abstract] [Full Text] [Related]
34. AIDS vaccines: is older better?
Cohen J
Science; 1992 Dec; 258(5090):1880-1. PubMed ID: 1470911
[No Abstract] [Full Text] [Related]
35. The biochemistry of AIDS.
Vaishnav YN; Wong-Staal F
Annu Rev Biochem; 1991; 60():577-630. PubMed ID: 1883204
[No Abstract] [Full Text] [Related]
36. Houdini's box: towards an understanding of AIDS virus escape from the cytotoxic T-lymphocyte response.
O'Connor DH; Watkins DI
Immunogenetics; 1999 Nov; 50(3-4):237-41. PubMed ID: 10602884
[No Abstract] [Full Text] [Related]
37. AIDS response.
Nature; 1991 Dec; 354(6353):439-40. PubMed ID: 1684222
[No Abstract] [Full Text] [Related]
38. Reservoir cells no longer detectable after a heterologous SHIV challenge with the synthetic HIV-1 Tat Oyi vaccine.
Watkins JD; Lancelot S; Campbell GR; Esquieu D; de Mareuil J; Opi S; Annappa S; Salles JP; Loret EP
Retrovirology; 2006 Jan; 3():8. PubMed ID: 16441880
[TBL] [Abstract][Full Text] [Related]
39. HIV vaccine development: perspective.
Bolognesi DP
Biotechnol Ther; 1991; 2(1-2):205-11. PubMed ID: 1845122
[No Abstract] [Full Text] [Related]
40. The advantage of early recognition of HIV-infected cells by cytotoxic T-lymphocytes.
Gruters RA; van Baalen CA; Osterhaus AD
Vaccine; 2002 May; 20(15):2011-5. PubMed ID: 11983265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
